Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 1 country.
Aurélie Maisonial-BessetUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.ORCID 0000-0003-0520-9156
Tiffany WitkowskiUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Mercedes QuintanaUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Sophie BesseUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Vincent GaumetUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.ORCID 0000-0002-8880-5764
Axel CordonnierUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Cyrille AlliotGIP Arronax, F-44800 Saint-Herblain, France.
Aurélien VidalGIP Arronax, F-44800 Saint-Herblain, France.
Caroline Denevault-SabourinGICC EA7501, Team IMT, Université de Tours, UFR de Médecine, Bâtiment Vialle, 10 Boulevard Tonnellé, BP 3223, CEDEX 01, 37032 Tours, France.ORCID 0000-0002-9901-7608
Sébastien TarritUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Sophie LevesqueDepartment of Nuclear Medicine, Jean Perrin Comprehensive Cancer Centre, F-63011 Clermont-Ferrand, France.
Elisabeth Miot-NoiraultUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.
Jean-Michel ChezalUniversité Clermont Auvergne, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, F-63000 Clermont-Ferrand, France.ORCID 0000-0001-7162-8450
Inserm · FRInstitut Génétique Nantes Atlantique · FRCentre Jean Perrin · FRUniversité de Tours · FR
Funding
Ligue contre le cancer, comité du Puy de Dôme Immuno-Tep, 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the · full record | OpenQuestion